Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.
Sign Up to like & getrecommendations! Published in 2020 at "Cell reports"
DOI: 10.1016/j.celrep.2020.107981
Abstract: The HIV fusion peptide (FP) is a promising vaccine target. FP-directed monoclonal antibodies from vaccinated macaques have been identified that neutralize up to ∼60% of HIV strains; these vaccinations, however, have involved ∼1 year with… read more here.
Keywords: immune monitoring; fusion peptide; imprint cross; neutralizing responses ... See more keywords
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the Pediatric Infectious Diseases Society"
DOI: 10.1093/jpids/piad015
Abstract: Abstract In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3,… read more here.
Keywords: immunogenicity safety; year olds; bnt162b2; neutralizing responses ... See more keywords
Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Virology"
DOI: 10.1128/jvi.01343-21
Abstract: It is generally accepted that an effective HIV-1 vaccine should be able to induce broad-spectrum neutralizing antibodies. Since most of these antibodies require long periods of somatic maturation in vivo, several groups are developing immunogens,… read more here.
Keywords: broadly neutralizing; early broadly; envelope; immunogens based ... See more keywords